January 25, 2022

The Honorable Jan Schakowsky  
2367 Rayburn House Office Building  
Washington, DC 20515

The Honorable Earl Blumenauer  
1111 Longworth House Office Building  
Washington, DC 20515

The Honorable Buddy Carter  
2432 Rayburn House Office Building  
Washington, DC 20515

The Honorable Mike Kelly  
1707 Longworth House Office Building  
Washington, DC 20515

RE: The Lymphedema Treatment Act (H.R.3630)

Dear Representatives Schakowsky, Carter, Blumenauer, and Kelly:

I am writing to you on behalf of Susan G. Komen to express support for the Lymphedema Treatment Act (H.R.3630) and gratitude for your leadership on this important issue. Amending the Medicare statute to enable coverage for prescribed medical compression garments will improve the lives of millions of Americans experiencing lymphedema, including many people living with breast cancer and survivors.

Komen is the world’s leading nonprofit breast cancer organization representing the millions of people who have been diagnosed with breast cancer. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts—we advocate for patients, drive research breakthroughs, improve access to high quality care, offer direct patient support and empower people with trustworthy information. Komen is committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. We advocate on behalf of the estimated 290,560 people in the United States who will be diagnosed with breast cancer and the 43,780 who will die from the disease in 2022 alone.

Breast cancer is the most common cancer diagnosed among women in the U.S. and is the second leading cause of cancer death among women after lung cancer. One in eight women in the U.S. will develop breast cancer over the course of her lifetime. With the increasing availability of mammography screening, earlier detection and improvements in breast cancer treatment, the overall breast cancer mortality rate among women in the U.S. declined by 41 percent over the last 30 years.\(^1\) However, statistics do not illustrate the challenges breast cancer patients and survivors face every day to maintain their health, including counteracting lymphedema.

Lymphedema affects an estimated 3-5 million people, with 1.5-3 million being Medicare beneficiaries. Lymphedema commonly develops from cancer treatments that remove or damage lymph nodes. Estimates of the incidence of breast cancer-related lymphedema ranges from 0 to 3% after lumpectomy alone to as high as 65 percent to 70 percent after modified radical mastectomy (removal of breast and axillary lymph nodes) with regional nodal radiation.\(^2\) People of color are disproportionately negatively impacted by the lack of coverage by Medicare of lymphedema treatment supplies. Recent data has

---


shown that black women are three and a half times more likely and Hispanic women are more than twice as likely than white women to develop breast cancer-related lymphedema. Furthermore, as survivorship increases, so too do the number of cases of lymphedema.

Medical compression garments are the essential cornerstone of treatment for lymphedema. Data demonstrates that the use of prescribed medical compression garments significantly improves health and quality of life for patients through reduced incidence of infections, hospitalizations, and other costly yet preventable complications. However, once acquired, patients must pay out-of-pocket expense associated with purchasing prescribed compression garments creating a significant barrier to treatment. Currently, Medicare does not fully cover compression garments, bandages, and devices needed for comprehensive lymphedema treatment.

Creating a new benefit category in Medicare for lymphedema compression supplies will very likely save the government money. A recent savings analysis from Avalere Health estimated that enactment of the Lymphedema Treatment Act will save the Medicare program $1.3 to $1.5 billion during the first 10 years, with additional savings likely. This bill is right for patients and right for the federal government’s budget.

Komen appreciates your leadership on the Lymphedema Treatment Act and stands ready to assist you in making it law. If you have any questions or we may be of further assistance, please do not hesitate to Aracely Panameño, Komen’s Director of Federal Policy and Advocacy at apanameno@komen.org or (972)701-2071.

Sincerely,

Molly Guthrie
Senior Director, Public Policy & Advocacy
Susan G. Komen

---